Message #69 From:
NewsBot Date: October 31, 2006 07:55:00 AM
NYMX News Nymox Pursuing Plans for Marketing Partnerships for Its NX-1207 BPH Drug
HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the
Company is in discussions with potential marketing partners for the
Company’s NX-1207 drug for the treatment of
benign prostatic hyperplasia (BPH), following the successful completion
of a placebo-controlled, double-blind, multi-center Phase 2 trial.
It is well-recognized within the industry that an effective treatment
for BPH would appeal to a large global market, particularly as the baby
boomer generation grows older and becomes more at risk for this common
affliction of older men. Paul Averback, CEO of Nymox said, “The
company has received positive inquiries from a number of attractive
potential partners in the global pharmaceutical industry and is actively
reviewing these opportunities.”
NX-1207 is Nymox’s innovative new treatment
for BPH. The company’s recently completed
Phase 2 trial showed positive efficacy and safety results for NX-1207.
Overall, patients treated with NX-1207 showed mean improvement of 9.35
points in AUA Symptom Score values, the standard scale used to evaluate
BPH drugs and treatments. This improvement compares favorably to the 3.5
to 5 point reported in published studies of currently approved drugs for
BPH and reached statistical significance when compared to placebo.
Subjects treated with NX-1207 also showed an overall significant
reduction in mean prostate volume. The results of the trial demonstrated
the excellent safety and side effect profile of NX-1207. Subjects
treated with NX-1207 had no serious side effects. In particular,
patients given NX-1207 had no (0%) significant sexual side effects.
BPH afflicts approximately half of men over age 50 and close to 90% of
men by age 80. The disorder causes difficulties with urination
associated with aging, such as urination at night, urge to void
frequently, hesitancy, weak stream, and other problems.
This press release contains certain “forward-looking
statements” as defined in the United States
Private Securities Litigation Reform Act of 1995 that involve a number
of risks and uncertainties. There can be no assurance that such
statements will prove to be accurate and the actual results and future
events could differ materially from management's current expectations.
The conduct of clinical trials and the development of drug products
involve substantial risks and uncertainties and actual results may
differ materially from expectations. Promising early results do not
ensure that later stage or larger scale clinical trials will be
successful or will proceed as expected. Such factors are detailed from
time to time in Nymox's filings with the United States Securities and
Exchange Commission and other regulatory authorities.
